PAD 4 Inhibitor

Emerging evidence indicates that neutrophil extracellular trap (NET) formation plays a role in driving inflammation and exacerbating organ injury in the setting of noninfectious, i.e. sterile, insult. Peptidylarginine deiminase 4 (PAD 4), an enzyme within neutrophils catalyzes NET formation. Consequently, inhibition of PAD 4 has been shown to mitigate acute kidney, liver and pancreatic injury. Using a drug development engine combining computational and medicinal chemistry with enzymatic bioassays, Angion is in the process of developing novel small molecule, parenteral use PAD 4 inhibitors for solid tissue injury.